Singapore markets open in 3 hours 4 minutes

CollPlant Biotechnologies Ltd. (CLGN)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.25-0.25 (-4.55%)
At close: 03:30PM EST
5.44 +0.09 (+1.68%)
After hours: 06:26PM EST
Full screen
Trade prices are not sourced from all markets
Previous close5.50
Open5.26
Bid4.75 x 1100
Ask8.41 x 1100
Day's range5.22 - 5.35
52-week range4.70 - 13.97
Volume19,345
Avg. volume12,631
Market cap60.127M
Beta (5Y monthly)0.71
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023

    CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the third quarter ended September 30, 2023, and provided a corporate update on its programs.

  • PR Newswire

    COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

    CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the third quarter of 2023 on Wednesday, November 29, 2023, before the market open. The Company will then host a conference call and webcast to discuss its financial results and corporate updates on November 29 at 10

  • PR Newswire

    CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler

    CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that the U.S. Patent and Trademark Office has granted a patent that covers CollPlant's photocurable dermal filler product candidate, being developed for the aesthetics market.